Patients with metastatic colorectal cancer (mCRC) who harbored BRAF
-dependent mutations were more likely to respond to anti-EGFR therapy versus those with BRAF
-independent mutations, according to results of a multicenter pooled analysis published in Clinical Cancer Research
- Patients with metastatic colorectal cancer harboring certain BRAF mutations may respond to anti-EGFR therapy. American Association for Cancer Research. Published September 12, 2019. https://bit.ly/2kbkJVE. Accessed September 12, 2019.
- Yaeger R, Kotani D. Mondaca S, et al. Response to anti-EGRR therapy in patients with BRAF non-V600-mutant metastatic colorectal cancer [published online September 12, 2019]. Clin Cancer Res. doi: 10.1158/1078-0432.CCR-19-2004.
... to read the full story